Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density lipoprotein (LDL) cholesterol (HMGCR, PCKS9, and NPC1L1 ) , high-density lipoprotein (HDL) cholesterol (CETP), or triglycerides (APOC3, ANGPTL3, ANGPTL4, and LPL). Conducting mendelian randomisation (MR) provided strong evidence of an effect of drug-based genetic scores on coronary artery disease (CAD) risk with the exception of ANGPTL3. We then systematically estimated the effects of each score on 249 metabolic traits derived using blood samples from an unprecedented sample size of up to 115,082 UK Biobank participants. Genetically predicted effects were generally consistent among drug targets, which were intended to modify the same lipoprotein lipid trait. For example, the linear fit for the MR estimates on all 249 metabolic traits for genetically predicted inhibition of LDL cholesterol lowering targets HMGCR and PCSK9 was r 2 = 0.91. In contrast, comparisons between drug classes that were designed to modify discrete lipoprotein traits typically had very different effects on metabolic signatures (for instance, HMGCR versus each of the 4 triglyceride targets all had r 2 < 0.02). Furthermore, we highlight this discrepancy for specific metabolic traits, for example, finding that LDL cholesterol lowering therapies typically had a weak effect on glycoprotein acetyls, a marker of inflammation, whereas triglyceride modifying therapies assessed provided evidence of a strong effect on lowering levels of this inflammatory biomarker. Our findings indicate that genetically predicted perturbations of these drug targets on the blood metabolome can drastically differ, despite largely consistent effects on risk of CAD, with potential implications for biomarkers in clinical development and measuring treatment response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetically proxied levels of lipids were significantly associated with CAD33,34”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ggplot2: Elegant Graphics for Data Analysis
Ginestet, C. (2011) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2010.00676_9.x · Cited by 13,726 · cited 1×
“All plots in this study were generated using the R package “ggplot2” [52].”
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728 · cited 1×
“Genetic instruments for each lipid-modifying drug target were selected by undertaking GWAS of lipoprotein lipid traits measured using a conventional biochemistry assay in UKB [44].”
The UK Biobank resource with deep phenotyping and genomic data
Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L. T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0579-z · Cited by 8,876
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711 · cited 1×
“We conducted linkage disequilibrium (LD) pruning for variants such that they had r 2 0.1 using a reference panel of 503 European individuals enrolled in the 1,000 Genomes Project phase 3 (version 5) [47].”
InfluentialMendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050 · cited 2×
“Two-sample MR analyses were undertaken using the inverse variance weighted (IVW) method while accounting for the correlation between instruments [22,23] ( Fig 1 ).”
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857 · cited 1×
“Circulating lipoprotein lipid concentrations are of central importance to the aetiology of CAD [2,3].”
Mahajan, A., Taliun, D., Thurner, M., Robertson, N. R., Torres, J. M., Rayner, N. W., Payne, A. J., Steinthorsdottir, V., Scott, R. A., Grarup, N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0241-6 · Cited by 1,744 · cited 1×
“Genetic estimates on T2D were extracted from a previous GWAS from the DIAMANTE consortium consisting of 74,124 cases and 824,006 controls of European ancestry [50].”
Efficient Bayesian mixed-model analysis increases association power in large cohorts
Loh, P.-R., Tucker, G., Bulik-Sullivan, B. K., Vilhjálmsson, B. J., Finucane, H. K., Salem, R. M., Chasman, D. I., Ridker, P. M., Neale, B. M., Berger, B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3190 · Cited by 1,507 · cited 1×
“…the BOLT-LMM (linear mixed model) software with adjustment for age, sex, fasting status (i.e., the interval between consumption of food or drink and blood samples being taken), and a binary variable denoting the genotyping chip used in individuals (the UKBB Axiom array or the UK BiLEVE array) [46].”
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483
Burgess, S., Dudbridge, F., & Thompson, S. G. (2016) · Statistics in Medicine · doi:10.1002/sim.6835 · Cited by 1,153
Sanderson, E., Davey Smith, G., Windmeijer, F., & Bowden, J. (2019) · International Journal of Epidemiology · doi:10.1093/ije/dyy262 · Cited by 1,085 · cited 1×
“In-depth investigations into the independent causal role of specific metabolic traits at a granular level can then be explored using approaches such as multivariable MR [37].”
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Richardson, T. G., Sanderson, E., Palmer, T. M., Ala-Korpela, M., Ference, B. A., Davey Smith, G., & Holmes, M. V. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003062 · Cited by 843
Self-citationCollider bias undermines our understanding of COVID-19 disease risk and severity
Griffith, G. J., Morris, T. T., Tudball, M. J., Herbert, A., Mancano, G., Pike, L., Sharp, G. C., Sterne, J., Palmer, T. M., Davey Smith, G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19478-2 · Cited by 826
Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801
Evinacumab for Homozygous Familial Hypercholesterolemia
Raal, F. J., Rosenson, R. S., Reeskamp, L. F., Hovingh, G. K., Kastelein, J. J. P., Rubba, P., Ali, S., Banerjee, P., Chan, K.-C., Gipe, D. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004215 · Cited by 793
Mendelian randomization of blood lipids for coronary heart disease
Holmes, M. V., Asselbergs, F. W., Palmer, T. M., Drenos, F., Lanktree, M. B., Nelson, C. P., Dale, C. E., Padmanabhan, S., Finan, C., Swerdlow, D. I., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/eht571 · Cited by 748
Self-citationVariation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Ference, B. A., Robinson, J. G., Brook, R. D., Catapano, A. L., Chapman, M. J., Neff, D. R., Voros, S., Giugliano, R. P., Davey Smith, G., Fazio, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604304 · Cited by 743
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Ference, B. A., Majeed, F., Penumetcha, R., Flack, J. M., & Brook, R. D. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.020 · Cited by 407
Using Mendelian Randomization to Improve the Design of Randomized Trials
Ference, B. A., Holmes, M. V., & Smith, G. D. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040980 · Cited by 338
Self-citationFuentes, A., Pineda, M., & Venkata, K. (2018) · Pharmacy · doi:10.3390/pharmacy6020043 · Cited by 337 · cited 1×
“Pharmacological therapies that target the metabolism of blood lipids are routinely used for the prevention and treatment of CVD and are among the most widely prescribed medicines in the world [8].”
Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304
Julkunen, H., Cichońska, A., Slagboom, P. E., Würtz, P., & Initiative, N. H. U. B. (2021) · eLife · doi:10.7554/elife.63033 · Cited by 207
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
Würtz, P., Wang, Q., Soininen, P., Kangas, A. J., Fatemifar, G., Tynkkynen, T., Tiainen, M., Perola, M., Tillin, T., Hughes, A. D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.060 · Cited by 188
Self-citationHolmes, M. V., Richardson, T. G., Ference, B. A., Davies, N. M., & Davey Smith, G. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00493-1 · Cited by 184 · cited 2×
“Such may be of utility from an early stage—for instance, during Phase I, II, and III clinical trials, where biomarkers are often used as a means of measuring treatment response across different concentrations of drugs [17], and postmar-keting, when assessing interindividual response to treatment.”
Self-citationBroadbent, J. R., Foley, C. N., Grant, A. J., Mason, A. M., Staley, J. R., & Burgess, S. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16374.1 · Cited by 151 · cited 1×
“MR analyses were conducted using the R package “MendelianRandomization” [53].”
Triangulating Evidence through the Inclusion of Genetically Informed Designs
Munafò, M. R., Higgins, J. P. T., & Smith, G. D. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a040659 · Cited by 125 · cited 1×
“Such diverse effects can then potentially be triangulated [36] to explore patterns of metabolomics where signatures are consistent with cardiovascular risk reduction.”
Wulff, A. B., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310473 · Cited by 117
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz, E., Kettunen, J., Holmes, M. V., Williams, C. O., Boachie, C., Wang, Q., Männikkö, M., Sebert, S., Walters, R., Lin, K., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034942 · Cited by 109
Self-citationRichardson, T. G., Hemani, G., Gaunt, T. R., Relton, C. L., & Smith, G. D. (2020) · Nature Communications · doi:10.1038/s41467-019-13921-9 · Cited by 89 · cited 1×
“…not carry this target forward into downstream analyses given the challenges for genetic confounding of conducting gene-centric MR analyses with a single genetic instrument, particularly in gene dense regions where the function of each gene is not well understood, which may hinder inference [48].”
Self-citationWang, Q., Oliver-Williams, C., Raitakari, O. T., Viikari, J., Lehtimäki, T., Kähönen, M., Järvelin, M.-R., Salomaa, V., Perola, M., Danesh, J., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa972 · Cited by 89
Self-citationCausal inference for heritable phenotypic risk factors using heterogeneous genetic instruments
Wang, J., Zhao, Q., Bowden, J., Hemani, G., Davey Smith, G., Small, D. S., & Zhang, N. R. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009575 · Cited by 88 · cited 2×
“This was to avoid overlapping samples in our planned MR analyses of metabolic traits, which has been reported to potentially lead to overfitting in estimates [20].”
Can Mendelian Randomization Shift into Reverse Gear?
Holmes, M. V., & Davey Smith, G. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2018.296806 · Cited by 67 · cited 1×
“Additional approaches including “reverse-MR” [38,39], where genetic instruments for liability to disease are explored for their metabolomic signatures, may reveal biomarkers on the causal pathway to disease.”
Self-citationRichardson, T. G., Wang, Q., Sanderson, E. C. M., Mahajan, A., McCarthy, M. I., Frayling, T. M., Ala‐Korpela, M., Sniderman, A. D., Smith, G. D., & Holmes, M. V. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00086-6 · Cited by 67
Self-citationHolmes, M. V., & Ala‐Korpela, M. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0157-6 · Cited by 65 · cited 1×
“This has implications on understanding which biomarkers to measure (for instance, during clinical development in randomised controlled trials) and on gauging markers of treatment response [16].”
Self-citationEmerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases
Geldenhuys, W. J., Lin, L., Darvesh, A. S., & Sadana, P. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.007 · Cited by 64
Bell, J. A., Richardson, T. G., Wang, Q., Sanderson, E. C. M., Palmer, T., Walker, V. M., O’Keeffe, L. M., Timpson, N. J., Cichońska, A., Julkunen, H., et al. (2022) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2022.100457 · Cited by 61
Self-citationLipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
Kettunen, J., Holmes, M. V., Allara, E., Anufrieva, O., Ohukainen, P., Oliver-Williams, C., Wang, Q., Tillin, T., Hughes, A. D., Kähönen, M., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000572 · Cited by 47
Self-citationAPOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia
Schmitz, J., & Gouni‐Berthold, I. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867324666170609081612 · Cited by 42 · cited 1×
“Therefore, while each of these drug classes has proven [9–11] or emerging [12–15] efficacy for CVD risk reduction, their effects on the blood lipidome and metabolome are likely to vary considerably.”
Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
Blauw, L. L., Noordam, R., Soidinsalo, S., Blauw, C. A., Li‐Gao, R., de Mutsert, R., Berbée, J. F. P., Wang, Y., van Heemst, D., Rosendaal, F. R., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0301-5 · Cited by 40
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 40
Mohammadi‐Shemirani, P., Sjaarda, J., Gerstein, H. C., Treleaven, D. J., Walsh, M. W., Mann, J. F. E., McQueen, M., Hess, S., & Paré, G. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2018.291104 · Cited by 18
FDA approves first anti-ANGPTL3 antibody, for rare cardiovascular indication
Mullard, A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/d41573-021-00047-1 · Cited by 14
Bell, J. A., Richardson, T. G., Wang, Q., et al. (2021) · medRxiv · doi:10.1101/2021.05.29.21258044 · Cited by 7
Self-citation
Research works printed but not linked: 1
- Mendes PFAPP Moura JMSP, 2020, New drugs coming up in the field of lipid control, e-Journal of Cardiology. Practice, 19
Cited by
Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank
Julkunen, H., Cichońska, A., Tiainen, M., Koskela, H., Nybo, K., Mäkelä, V., Nokso-Koivisto, J., Kristiansson, K., Perola, M., Salomaa, V., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36231-7 · Cited by 536
Genome-wide characterization of circulating metabolic biomarkers
Karjalainen, M. K., Karthikeyan, S., Oliver-Williams, C., Sliz, E., Allara, E., Fung, W. T., Surendran, P., Zhang, W., Jousilahti, P., Kristiansson, K., et al. (2024) · Nature · doi:10.1038/s41586-024-07148-y · Cited by 261
Short Chain Fatty Acid Metabolism in Relation to Gut Microbiota and Genetic Variability
Ramos Meyers, G., Samouda, H., & Bohn, T. (2022) · Nutrients · doi:10.3390/nu14245361 · Cited by 184
Mansour, A., Mousa, M., Abdelmannan, D. K., Tay, G. K., Hassoun, A. A. K., & AlSafar, H. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1143067 · Cited by 178
Li, Z., Zhang, B., Liu, Q., Tao, Z., Ding, L., Guo, B., Zhang, E., Zhang, H., Meng, Z., Guo, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104543 · Cited by 148
Metadata
- Authors
- Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V.
- Affiliations
- University of Bristol (GB)
- University of Oxford (GB)
- Corresponding author
- Richardson, Tom G.
- ORCID
- Venue
- PLOS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-02-25
- Volume
- 20
- Issue
- 2
- Pages
- e3001547
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC8906647
- OpenAlex
- W4214506665
- Cited by
- 304
- References
- 51
- Citations by year
- 2026: 52 · 2025: 103 · 2024: 95 · 2023: 41 · 2022: 12
- FWCI
- 60.45
- Type
- journal article
- Language
- en
- Update notices
- new_version (2022-03-09)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Biology (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion, cc-by-nc)
- Explore Bristol Research (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- British Heart Foundation (FS/18/23/33512)
- Medical Research Council (MC_UU_00011/1)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Keywords
- lipid therapy, Mendelian randomization, blood metabolome, coronary artery disease risk, LDL cholesterol lowering, triglyceride lowering, HMGCR, PCSK9, NPC1L1, cholesteryl ester transfer protein, apolipoprotein C-III, ANGPTL3, ANGPTL4, lipoprotein lipase, glycoprotein acetyls, inflammatory markers, metabolic phenotypes, treatment response biomarkers
- MeSH terms
- Proprotein Convertase 9, Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Cholesterol, Humans, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Triglycerides, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.